Angelini adds registrational epilepsy program via $610M Arvelle takeout

Via its $960 million takeout of Swiss CNS play Arvelle, Angelini will gain European rights to a late-stage epilepsy program. 

The deal, which includes $610 million in cash up front and up to $350 million in milestones, comes less than two years after  Arvelle Therapeutics GmbH spun out of Axovant Sciences Ltd. (NASDAQ:AXON) in February 2019 with more than $100 million in financing and in-licensed exclusive European rights to anti-epileptic cenobamate from SK Biopharmaceuticals Co. Ltd...